FUNDC1 FFUNDC1, a mitochondrial outer membrane protein, induces mitophagy in mammalian cells under low oxygen conditions [18]
In addition to its role in regulating seasonal physiology and influencing the circadian system and sleep patterns, melatonin is involved in cell protection, neuroprotection, and the reproductive system, among other possible functions
Support metabolic function
The IGF-1R is mainly involved in regulation of cell proliferation, antiapoptosis, differentiation and cell motility, whereas IR is mostly of impact for control of glucose uptake and metabolism
At 20mg/mL concentration with the 1.0mL reconstitution, each unit on your syringe delivers exactly 200mcg
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
